BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11846617)

  • 1. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.
    Tentori L; Portarena I; Graziani G
    Pharmacol Res; 2002 Feb; 45(2):73-85. PubMed ID: 11846617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline
    Alaklabi S; Roy AM; Chaudhary LN; Gandhi S
    Explor Target Antitumor Ther; 2023; 4(6):1301-1309. PubMed ID: 38213539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic analysis reveals the molecular mechanism of Astragaloside in the treatment of non-small cell lung cancer by inducing apoptosis.
    Liu J; Sun Y; Chen W; Deng L; Chen M; Dong J
    BMC Complement Med Ther; 2023 Dec; 23(1):461. PubMed ID: 38102661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of the Development of PARP Inhibitors.
    Plummer R
    Cancer Treat Res; 2023; 186():1-11. PubMed ID: 37978127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Counting the cost of public and philanthropic R&D funding: the case of olaparib.
    Schmidt L; Sehic O; Wild C
    J Pharm Policy Pract; 2022 Aug; 15(1):47. PubMed ID: 35974344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.
    Tiwari P; Khan H; Singh TG; Grewal AK
    Neurochem Res; 2022 Jul; 47(7):1830-1852. PubMed ID: 35437712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.
    Jette NR; Kumar M; Radhamani S; Arthur G; Goutam S; Yip S; Kolinsky M; Williams GJ; Bose P; Lees-Miller SP
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-ribose) polymerase inhibition reveals a potential mechanism to promote neuroprotection and treat neuropathic pain.
    Komirishetty P; Areti A; Gogoi R; Sistla R; Kumar A
    Neural Regen Res; 2016 Oct; 11(10):1545-1548. PubMed ID: 27904474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased Poly(ADP-Ribose) Polymerase 1 Expression Attenuates Glucose Oxidase-Induced Damage in Rat Cochlear Marginal Strial Cells.
    Zhang Y; Yang Y; Xie Z; Zuo W; Jiang H; Zhao X; Sun Y; Kong W
    Mol Neurobiol; 2016 Nov; 53(9):5971-5984. PubMed ID: 26526840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard of care and promising new agents for triple negative metastatic breast cancer.
    Mancini P; Angeloni A; Risi E; Orsi E; Mezi S
    Cancers (Basel); 2014 Oct; 6(4):2187-223. PubMed ID: 25347122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.
    Sabbatino F; Fusciello C; Somma D; Pacelli R; Poudel R; Pepin D; Leonardi A; Carlomagno C; Della Vittoria Scarpati G; Ferrone S; Pepe S
    Cytometry A; 2014 Nov; 85(11):953-61. PubMed ID: 25182801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolated limb infusion as a model to test new agents to treat metastatic melanoma.
    Lidsky ME; Speicher PJ; Jiang B; Tsutsui M; Tyler DS
    J Surg Oncol; 2014 Mar; 109(4):357-65. PubMed ID: 24522940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP inhibition attenuates histopathological lesion in ischemia/reperfusion renal mouse model after cold prolonged ischemia.
    del Moral RM; Gómez-Morales M; Hernández-Cortés P; Aguilar D; Caballero T; Aneiros-Fernández J; Caba-Molina M; Rodríguez-Martínez MD; Peralta A; Galindo-Moreno P; Osuna A; Oliver FJ; del Moral RG; O'Valle F
    ScientificWorldJournal; 2013; 2013():486574. PubMed ID: 24319370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.
    Tokuhisa Y; Lidsky ME; Toshimitsu H; Turley RS; Beasley GM; Ueno T; Sharma K; Augustine CK; Tyler DS
    Ann Surg Oncol; 2014 Mar; 21(3):1024-30. PubMed ID: 24281418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.
    Booth L; Cruickshanks N; Ridder T; Dai Y; Grant S; Dent P
    Cancer Biol Ther; 2013 May; 14(5):458-65. PubMed ID: 23917378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.
    Curtin NJ
    Br J Pharmacol; 2013 Aug; 169(8):1745-65. PubMed ID: 23682925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
    Tang Y; Hamed HA; Poklepovic A; Dai Y; Grant S; Dent P
    Mol Pharmacol; 2012 Aug; 82(2):322-32. PubMed ID: 22596349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
    Plummer R
    Breast Cancer Res; 2011 Aug; 13(4):218. PubMed ID: 21884642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP.
    Kim H; Naura AS; Errami Y; Ju J; Boulares AH
    Mol Med; 2011; 17(9-10):893-900. PubMed ID: 21607289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.